| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.6 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.092 | 0.6 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.6 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | -0.032 | 0.6 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.032 | 0.6 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.029 | 0.6 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |